Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IcICLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL.

Trial Profile

IcICLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Obinutuzumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms IciCLLe
  • Most Recent Events

    • 04 Dec 2018 Results assessing Ibrutinib and Obinutuzumab in CLL patients with >1 Year Prior Ibrutinib Exposure, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 17 Jun 2018 Results (from ADMIRE, ARCTIC, IcICLLe and CLARITY trials) quantifying CLL cell percent of leucytes (%MRD) using 8CLR ERIC-standard flow cytometry (detection limit 10-5/0.001%) presented at the 23rd Congress of the European Haematology Association
    • 25 Jun 2017 Initial results (n=31) from extension study presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top